Clinical Trial Update: Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety, tolerability, pharmacokinetics, and efficacy of AZD5213 in adolescents with Tourette syndrome; results posted after study compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tourette Syndrome

Drugs mentioned

• AZD5213 (AZD5213)

Snippet

Sponsor: AstraZeneca | Conditions: Tourette Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2016-07-25